Combined antihypertensive and lipid-lowering treatment

被引:0
|
作者
Maurizio Cesari
Achille C. Pessina
机构
[1] University of Padova,Department of Clinical and Experimental Medicine, Clinica Medica 4
来源
关键词
Statin; Pravastatin; Cerivastatin; Lacidipine; Cholesteryl Ester Hydrolase;
D O I
暂无
中图分类号
学科分类号
摘要
Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk. Current guidelines on cardiovascular prevention strongly recommend treating both disorders. Unfortunately, the low treatment and control rates, combined with the high prevalence of both conditions, still contribute to the high burden of cardiovascular disease in Western countries. In the past 5 years, many studies evaluating the benefit of combined antihypertensive and lipid-lowering treatment on endothelial dysfunction, coronary atherosclerosis, hypertension control, and on primary and secondary prevention of cardiovascular events have been published. In this article, we discuss and critically evaluate the available evidence on the potential benefits of combined antihypertensive and lipid-lowering treatment.
引用
收藏
页码:300 / 306
页数:6
相关论文
共 50 条
  • [1] Combined antihypertensive and lipid-lowering treatment
    Cesari, M
    Pessina, AC
    CURRENT HYPERTENSION REPORTS, 2004, 6 (04) : 300 - 306
  • [2] COMBINED ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY IN EXPERIMENTAL GLOMERULONEPHRITIS
    RUBIN, R
    SILBIGER, S
    SABLAY, L
    NEUGARTEN, J
    HYPERTENSION, 1994, 23 (01) : 92 - 95
  • [3] COMBINED LIPID-LOWERING AND ANTIHYPERTENSIVE TREATMENT AS PART OF A STRATEGY OF MULTIPLE RISK FACTOR INTERVENTION
    MACDONALD, NJ
    FARISH, E
    STARK, S
    BARNES, JF
    ROLTON, H
    SABA, SN
    ELLIOTT, HL
    REID, JL
    JOURNAL OF HUMAN HYPERTENSION, 1991, 5 (05) : 449 - 454
  • [4] Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?
    Kuang, Ze-Min
    CARDIOLOGY RESEARCH AND PRACTICE, 2020, 2020
  • [5] The antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Flack, JM
    Nasser, SA
    CURRENT HYPERTENSION REPORTS, 2003, 5 (03) : 189 - 191
  • [6] Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010
    Tuppin, Philippe
    Ricci-Renaud, Pauline
    de Peretti, Christine
    Fagot-Campagna, Anne
    Gastaldi-Menager, Christelle
    Danchin, Nicolas
    Alla, Francois
    Allemand, Hubert
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (05) : 274 - 286
  • [7] Adherence with concomitant antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Battleman, DS
    Schwartz, S
    CIRCULATION, 2003, 108 (17) : 756 - 757
  • [8] Predictors of adherence with antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Collins, SR
    Battleman, DS
    Schwartz, JS
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1147 - 1152
  • [9] Cardiovascular Pharmacogenetics of Antihypertensive and Lipid-Lowering Therapies
    Vanichakarn, P.
    Hwa, J.
    Stitham, J.
    CURRENT MOLECULAR MEDICINE, 2014, 14 (07) : 849 - 879
  • [10] Adherence With Lipid-Lowering, Antihypertensive, and Diabetes Medications
    Davis, James W.
    Fujimoto, Ronald Y.
    Chan, Henry
    Juarez, Deborah T.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (03) : 165 - 171